Brooks Laboratories is spinning off its Baddi manufacturing business into a separate subsidiary, Abridge Speciality Limited. Existing shareholders will receive a 1:1 share entitlement in the new entity, which will eventually be renamed Brooks Laboratories Limited, while the current firm transitions to Xuri Lifesciences. The move aims to split manufacturing and trading operations, though it remains subject to regulatory approvals over the next 16 months.
Brooks Laboratories Announces Strategic Demerger of Manufacturing Business
Manufacturing business revenue contribution: Rs 82.87 crore (96.66% of turnover).
Share entitlement ratio: 1 share of Abridge Speciality for every 1 share held in Brooks Laboratories.
Reader Takeaway: Shareholders gain two distinct business entities, but must monitor a complex 16-month regulatory approval process.
What just happened
Brooks Laboratories Ltd has received board approval for a formal Scheme of Arrangement to demerge its manufacturing business located at Baddi into its wholly-owned subsidiary, Abridge Speciality Limited. Upon completion, the new entity will be renamed Brooks Laboratories Limited, while the current parent company will be renamed Xuri Lifesciences Limited, shifting its focus toward trading activities.
Why this matters
The demerger is designed to provide greater strategic focus by separating the capital-intensive manufacturing operations from the company's trading business. By creating two distinct corporate platforms, management aims to align ownership with promoter groups and allow the manufacturing business to pursue independent growth and capital requirements.
The backstory
The Baddi manufacturing unit is the core driver of the company's financial profile, accounting for 96.66% of the firm's FY26 turnover. The current structure blends manufacturing, exports, and contract manufacturing with trading activities; the board believes this separation will unlock value and provide clearer operational visibility.
Risks to watch
Investors should note the significant timeline, with listing expected in approximately 16 months. The scheme is subject to rigorous regulatory hurdles, including approvals from the NCLT, SEBI, stock exchanges, and company creditors. Operational continuity during this 16-month transition period remains a critical factor for success.
What to track next
The implementation process will unfold in stages: initial regulatory filings and exchange approvals over the first six months, followed by NCLT motions, and finally the allotment and listing of the resulting entities. Investors should watch for the official NCLT first motion and subsequent shareholder meeting announcements.